Brightseed, a life sciences company specializing in AI-assisted discovery of bioactives, announced the launch of an innovation platform available to customers, designed to increase the probability of commercial success across health and life science product launches.

The company will evolve from a focus on discovering new molecules itself to one that is based on delivering “data as a service” (DaaS) to global health science organizations. The technology used in this platform allowed Brightseed to commercialize AI-discovered bioactive molecules, including offerings for glucose control and digestive health.

According to the company, more than 75% of products in health and life sciences fail to reach the market due to “fragmented workflows, disconnected data, and late-stage risk discovery.” The innovation platform helps to connect discovery, development, and commercialization in one place, preserving scientific insight, evidence, and decisions across the product’s life cycle.

The program is powered by Forager, the company’s AI-powered discovery engine, built on a data set of more than 11 million natural compounds evaluated across 23 categories of health. While general-purpose AI systems are trained on public data, Brightseed’s platform is grounded in proprietary data.

“Health innovation has operated on a broken probability curve for decades,” said Lee Chae, PhD, co-founder and CEO. “We built our innovation platform to fundamentally change that curve. By converging deep biological insight, proprietary multi-omics datasets, and cutting-edge AI and machine learning architecture into a continuous innovation fountain, we are defining a new category, one where AI is not an add-on, but the core operating foundation of life sciences innovation.”

Brightseed has more than 40 partnerships across consumer health, nutrition, personal care, pharmaceuticals, and animal health, and is transitioning customers to a recurring subscription model aligned with its platform strategy.